Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma.

e15095 Background: Gemcitabine (G) plus Capecitabine (C) have demonstrated a modest activity in metastatic renal cell cancer (mRCC) patients (pts). The combination of Sunitinib (S) and C resulted i...